1. [Imatinib plasma levels in the management of cutaneous side effects induced by imatinib (Glivec®): 2 case reports].
- Author
-
Trabelsi S, Gaïes E, Sraïri S, Sahnoun R, Daghfous R, Lakhal M, El Aïdli S, and Klouz A
- Subjects
- Aged, Antineoplastic Agents adverse effects, Antineoplastic Agents blood, Benzamides therapeutic use, Drug Eruptions blood, Drug Eruptions complications, Drug Eruptions etiology, Exanthema blood, Exanthema complications, Female, Humans, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy, Male, Middle Aged, Piperazines therapeutic use, Pruritus chemically induced, Pruritus complications, Pruritus therapy, Pyrimidines therapeutic use, Benzamides adverse effects, Benzamides blood, Drug Eruptions therapy, Exanthema chemically induced, Exanthema therapy, Piperazines adverse effects, Piperazines blood, Pyrimidines adverse effects, Pyrimidines blood
- Abstract
Imatinib, an antineoplastic drug used to treat certain cancers, has many side effects such as hematologic, neurologic or cutaneous toxicity. These toxicities seem to be due to a high imatinib plasmatic concentration and are frequently controlled by a discontinuation or a dosage reduction of the drug. We report here in 2 cases of cutaneous side effects induced by imatinib in order to demonstrate the necessity of drug monitoring in such cases. In our cases, imatinib is responsible in the occurrence of these side effects. Monitoring plasma levels of imatinib allowed us to judge if levels were toxic or not and to avoid discontinuation of imatinib in some cases.
- Published
- 2013
- Full Text
- View/download PDF